Semaglutide helps resolve nonalcoholic steatohepatitis
The glucagon-like peptide-1 receptor agonist semaglutide appears safe and effective in the treatment of patients with nonalcoholic steatohepatitis (NASH), resulting in a higher rate of resolution than placebo, according to the results of a phase II trial. There is, however, little effect on fibrosis stage.